Analyst Price Targets — BBNX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2026 10:20 am | — | Goldman Sachs | $19.00 | $16.86 | TheFly | Beta Bionics price target raised to $19 from $17 at Goldman Sachs |
| July 13, 2026 1:48 pm | — | Truist Financial | $22.00 | $17.26 | TheFly | Beta Bionics price target raised to $22 from $18 at Truist |
| May 27, 2026 10:17 am | — | Goldman Sachs | $17.00 | $11.72 | TheFly | Beta Bionics price target lowered to $17 from $19 at Goldman Sachs |
| February 18, 2026 1:42 pm | — | Lake Street | $20.00 | $12.45 | TheFly | Beta Bionics price target lowered to $20 from $40 at Lake Street |
| February 18, 2026 12:47 pm | — | Robert W. Baird | $14.00 | $13.97 | TheFly | Beta Bionics price target lowered to $14 from $28 at Baird |
| February 18, 2026 11:47 am | Jonathan Block | Stifel Nicolaus | $22.00 | $13.97 | TheFly | Beta Bionics price target lowered to $22 from $25 at Stifel |
| February 8, 2026 9:13 pm | — | UBS | $24.00 | $13.08 | TheFly | Beta Bionics initiated with a Buy at UBS |
| February 4, 2026 1:09 pm | — | Stifel Nicolaus | $25.00 | $14.06 | TheFly | Beta Bionics price target lowered to $25 from $31 at Stifel |
| February 2, 2026 2:54 pm | — | Truist Financial | $25.00 | $13.90 | TheFly | Beta Bionics price target lowered to $25 from $37 at Truist |
| January 26, 2026 9:41 pm | — | Cowen & Co. | $17.00 | $15.46 | TheFly | Beta Bionics initiated with a Hold at TD Cowen |
Latest News for BBNX
SAN DIEGO, July 1, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook,…
IRVINE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2026 financial results after the financial markets close on Wednesday, July 29, 2026.
SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business…
SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business…
SAN DIEGO, June 22, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook,…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BBNX.
U.S. House Trading
No House trades found for BBNX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.